MRSN

Mersana Therapeutics, Inc. [MRSN] Stock Forecast

Q: What is Mersana Therapeutics, Inc. stock symbol ?

Mersana Therapeutics, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol MRSN

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MRSN Stock Summary

Earnings have grown 38.65% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 40.72%

Earnings are expected to fall -100% next year

Profit margins (-4.87%) are lower than the previous year (-4.66%)

MRSN has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

MRSN

Top 10 Correlated Stocks

MRSN

In the News

MRSN Financial details

Company Rating

Neutral

Market Cap

459.42M

Income

-172.65M

Revenue

36.86M

Book val./share

0.31

Cash/share

1.73

Dividend

Dividend %

Employees

228

Optionable

Shortable

Yes

Earnings

26 Feb 2024

P/E

-1.96

Forward P/E

PEG

0.61

P/S

9.54

P/B

7.46

P/C

1.93

P/FCF

-2.7

Quick Ratio

3.55

Current Ratio

3.68

Debt / Equity

0.78

LT Debt / Equity

0.63

EPS (TTM)

-1.51

EPS next Y

EPS next Q

EPS this Y

-33.33%

EPS next Y

EPS next 5Y

EPS last 5Y

18.63%

Revenue last 5Y

-2.64%

Revenue Q/Q

39.01%

EPS Q/Q

-54.29%

SMA20

-20%

SMA50

SMA100

100%

Inst Own

75.51%

Inst Trans

0.72%

ROA

-76%

ROE

-267%

ROC

-1.01%

Gross Margin

100%

Oper. Margin

-483%

Profit Margin

-487%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.801-9.62

52W High

52W Low

RSI

Rel Volume

0.37

Avg Volume

2.18M

Volume

811.42K

Perf Week

-9.97%

Perf Month

-42.91%

Perf Quarter

177.18%

Perf Half Y

101.2%

Beta

1.372

Volatility

0.17%, 0.67%

Prev Close

-5.11%

Price

3.34

Change

-11.64%

MRSN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.97	0.01	0	0.28	0.32
Net income per share	-0.63	-1.44	-2.4	-2.22	-1.48
Operating cash flow per share	-1.56	-1.21	-1.98	-0.53	-1.45
Free cash flow per share	-1.57	-1.22	-1.99	-0.55	-1.47
Cash per share	2.29	4.15	2.52	4.62	1.8
Book value per share	1.8	3.71	1.72	0.98	0.32
Tangible book value per share	1.8	3.71	1.72	0.98	0.32
Share holders equity per share	1.8	3.71	1.72	0.98	0.32
Interest debt per share	0.18	0.28	0.56	0.42	0.28
Market cap	249.21M	1.64B	439.01M	548.81M	269.38M
Enterprise value	194.62M	1.4B	299.24M	304.4M	128.65M
P/E ratio	-9.16	-18.51	-2.59	-2.64	-1.57
Price to sales ratio	5.92	1.98K	10.21K	20.65	7.31
POCF ratio	-3.68	-21.9	-3.14	-11.12	-1.6
PFCF ratio	-3.65	-21.77	-3.12	-10.64	-1.57
P/B Ratio	3.18	7.17	3.61	5.96	7.3
PTB ratio	3.18	7.17	3.61	5.96	7.3
EV to sales	4.62	1.69K	6.96K	11.45	3.49
Enterprise value over EBITDA	-6.96	-16.12	-1.77	-1.49	-0.76
EV to operating cash flow	-2.87	-18.71	-2.14	-6.17	-0.76
EV to free cash flow	-2.85	-18.59	-2.13	-5.9	-0.75
Earnings yield	-0.11	-0.05	-0.39	-0.38	-0.64
Free cash flow yield	-0.27	-0.05	-0.32	-0.09	-0.63
Debt to equity	0.1	0.07	0.31	0.39	0.78
Debt to assets	0.07	0.06	0.19	0.11	0.13
Net debt to EBITDA	1.95	2.75	0.83	1.2	0.83
Current ratio	4.21	8.62	3.97	3.49	3.36
Interest coverage	-124.87	-244.25	-133.95	-61.51	-41.97
Income quality	2.4	0.85	0.82	0.24	0.98
Dividend Yield	0	0	0	0	0.35
Payout ratio	-0.02	-0.01	0	0	-0.55
Sales general and administrative to revenue	0.41	26.45	857.86	2.14	1.62
Research and developement to revenue	1.31	80.96	3.07K	6.52	4.02
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0	0.04	0.01
Capex to revenue	-0.01	-0.57	-15.07	-0.08	-0.06
Capex to depreciation	-0.49	-0.47	-0.76	-2.37	-1.43
Stock based compensation to revenue	0.12	8.66	428.12	0.81	0.57
Graham number	5.03	10.95	9.65	7	3.25
ROIC	-0.32	-0.34	-0.97	-1.49	-2.42
Return on tangible assets	-0.25	-0.32	-0.82	-0.62	-0.76
Graham Net	1.62	3.41	1.33	2.27	0.17
Working capital	77.26M	228.58M	141.38M	227.69M	150.42M
Tangible asset value	78.32M	228.09M	121.74M	92.06M	36.9M
Net current asset value	72.1M	213.27M	104.53M	76.94M	24.9M
Invested capital	0.1	0.07	0.31	0.39	0.78
Average receivables	229.5K	0	0	15M	15M
Average payables	9.01M	7.82M	10.33M	13.14M	10.64M
Average inventory	-2.09M	0	0	0	0
Days sales outstanding	0	0	0	411.95	0
Days payables outstanding	48.38	45.41	34.07	5.49K	1.76K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0.89	0
Payables turnover	7.54	8.04	10.71	0.07	0.21
Inventory turnover	0	0	0	0	0
ROE	-0.35	-0.39	-1.39	-2.25	-4.65
Capex per share	-0.01	-0.01	-0.01	-0.02	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.15	0.07	0.09	0.06	0.09
Net income per share	-0.45	-0.53	-0.47	-0.35	-0.16
Operating cash flow per share	-0.51	-0.27	-0.53	-0.38	-0.28
Free cash flow per share	-0.51	-0.28	-0.54	-0.39	-0.29
Cash per share	4.28	2.55	3.84	2	1.73
Book value per share	0.91	0.6	0.78	0.43	0.31
Tangible book value per share	0.91	0.6	0.78	0.43	0.31
Share holders equity per share	0.91	0.6	0.78	0.43	0.31
Interest debt per share	0.37	0.34	0.31	0.28	0.25
Market cap	591.94M	441.89M	380.35M	153.06M	279.83M
Enterprise value	347.53M	354.74M	128.79M	1.12M	139.09M
P/E ratio	-3.22	-1.93	-1.75	-0.92	-3.58
Price to sales ratio	40.3	56.64	35.7	19.88	26.15
POCF ratio	-11.55	-15.23	-6.15	-3.32	-8.19
PFCF ratio	-11.38	-14.77	-6.11	-3.29	-8.1
P/B Ratio	6.43	6.87	4.24	2.93	7.58
PTB ratio	6.43	6.87	4.24	2.93	7.58
EV to sales	23.66	45.47	12.09	0.15	13
Enterprise value over EBITDA	-7.58	-6.47	-2.28	-0.03	-6.79
EV to operating cash flow	-6.78	-12.23	-2.08	-0.02	-4.07
EV to free cash flow	-6.68	-11.86	-2.07	-0.02	-4.03
Earnings yield	-0.08	-0.13	-0.14	-0.27	-0.07
Free cash flow yield	-0.09	-0.07	-0.16	-0.3	-0.12
Debt to equity	0.39	0.55	0.39	0.66	0.78
Debt to assets	0.11	0.12	0.11	0.13	0.13
Net debt to EBITDA	5.33	1.59	4.45	3.65	6.87
Current ratio	3.49	3.38	3.97	3.68	3.36
Interest coverage	-47.83	-56.13	-52.98	40.96	-19.97
Income quality	1.14	0.52	1.14	1.11	1.75
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	-0.01	-0.01
Sales general and administrative to revenue	1.01	2.35	1.71	1.67	0.95
Research and developement to revenue	3.11	6.06	4.6	3.97	2.01
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.02	0.03	0.01	0.01	0.01
Capex to revenue	-0.05	-0.12	-0.04	-0.06	-0.04
Capex to depreciation	-2.78	-2.86	-1.23	-1.11	-0.86
Stock based compensation to revenue	0.36	0.82	0.62	0.52	0.38
Graham number	3.05	2.67	2.87	1.84	1.06
ROIC	-0.34	-0.51	-0.4	-0.37	-0.38
Return on tangible assets	-0.14	-0.19	-0.17	-0.16	-0.09
Graham Net	2.11	0.39	1.93	0.25	0.17
Working capital	227.69M	198.41M	222.17M	181.81M	150.42M
Tangible asset value	92.06M	64.29M	89.8M	52.2M	36.9M
Net current asset value	76.94M	49.91M	75.89M	39.03M	24.9M
Invested capital	0.39	0.55	0.39	0.66	0.78
Average receivables	15M	15M	0	0	0
Average payables	13.84M	16.05M	17.54M	14.93M	10.13M
Average inventory	0	0	0	0	0
Days sales outstanding	183.82	0	0	0	0
Days payables outstanding	4.45K	5.12K	4.7K	2.73K	1.47K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0.49	0	0	0	0
Payables turnover	0.02	0.02	0.02	0.03	0.06
Inventory turnover	0	0	0	0	0
ROE	-0.5	-0.89	-0.6	-0.8	-0.53
Capex per share	-0.01	-0.01	0	0	0

MRSN Frequently Asked Questions

What is Mersana Therapeutics, Inc. stock symbol ?

Mersana Therapeutics, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol MRSN

What is Mersana Therapeutics, Inc. stock quote today ?

Mersana Therapeutics, Inc. stock price is $3.34 today.

Is Mersana Therapeutics, Inc. stock public?

Yes, Mersana Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.18M
Market Capitalization 459.42M
Employee 228
CEO Dr. Martin H. Huber Jr., M.D.
Headquarters Cambridge,MA,US
IPO Date 2017-06-28
Website https://www.mersana.com

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.